{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:24:25Z","timestamp":1786944265078,"version":"build-2736575974"},"reference-count":130,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Antibody-drug conjugates (ADCs) have made important advances in the treatment of bladder cancer (BC) in recent years and have demonstrated significant clinical benefit in locally advanced or metastatic urothelial carcinoma (UC). However, the emergence of resistance remains a key factor limiting the durability of their therapeutic efficacy. Current evidence indicates that resistance to ADCs in BC is a complex process driven by multiple tumor-intrinsic and tumor-extrinsic factors. This review systematically summarizes the major mechanisms underlying ADC resistance in BC and outlines potential strategies to overcome it, including the development of next-generation ADCs, combination therapies, and predictive biomarkers. A deeper understanding of BC-specific mechanisms of ADC resistance will help promote the development of more precise and individualized ADC-based treatment strategies.<\/jats:p>","DOI":"10.3389\/fphar.2026.1882868","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:31:55Z","timestamp":1786941115000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanisms of resistance to antibody-drug conjugates in bladder cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Kai","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feixiang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nrurol.2015.292","article-title":"The interplay of extracellular matrix and microbiome in urothelial bladder cancer","volume":"13","author":"Alfano","year":"2016","journal-title":"Nat. Rev. Urol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41568-023-00574-6","article-title":"Endocytosis in cancer and cancer therapy","volume":"23","author":"Banushi","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/sj.bjc.6602026","article-title":"Role of urothelial cells in BCG immunotherapy for superficial bladder cancer","volume":"91","author":"Bevers","year":"2004","journal-title":"Br. J. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1038\/s42003-023-05668-3","article-title":"Transcriptional state dynamics lead to heterogeneity and adaptive tumor evolution in urothelial bladder carcinoma","volume":"6","author":"Biswas","year":"2023","journal-title":"Commun. Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11912-023-01360-1","article-title":"Nectin-4: a tumor cell target and status of inhibitor development","volume":"25","author":"Bouleftour","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.1158\/1078-0432.CCR-24-1393","article-title":"FDA approval summary: Enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma","volume":"30","author":"Brave","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. For Clin."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/1535-7163.MCT-22-0013","article-title":"Overcoming resistance to anti-nectin-4 antibody-drug conjugate","volume":"21","author":"Cabaud","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1158\/0008-5472.CAN-17-2391","article-title":"Cathepsin B is dispensable for cellular processing of cathepsin B-Cleavable antibody-drug conjugates","volume":"77","author":"Caculitan","year":"2017","journal-title":"Cancer Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA approval summary: Enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions","volume":"24","author":"Chen","year":"2025","journal-title":"Mol. Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cac2.12387","article-title":"Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun."},{"key":"B14","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s10495-024-02044-2","article-title":"Single-cell RNA sequencing analysis reveals the dynamic changes in the tumor microenvironment during NMIBC recurrence","volume":"30","author":"Chen","year":"2025","journal-title":"Apoptosis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41585-025-01092-w","article-title":"The hypoxic ECM and neutrophils in MIBC immunotherapy resistance","volume":"23","author":"Child","year":"2025","journal-title":"Nat. Rev. Urol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.euo.2021.11.005","article-title":"TROP2 expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells","volume":"5","author":"Chou","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/jcp.22773","article-title":"Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy","volume":"227","author":"Ciravolo","year":"2012","journal-title":"J. Cell. Physiology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41571-025-01095-x","article-title":"Towards biomarker-driven therapies for urothelial carcinoma","volume":"23","author":"Coca Membribes","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e09933","DOI":"10.1002\/advs.202509933","article-title":"A novel FGFR3-Targeting antibody-drug conjugate induces tumor cell apoptosis through the cGAS-STING pathway in bladder cancer","volume":"13","author":"Cui","year":"2026","journal-title":"Adv. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s40265-021-01614-x","article-title":"Disitamab vedotin: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1021\/acs.bioconjchem.7b00013","article-title":"Improved lysosomal trafficking can modulate the potency of antibody drug conjugates","volume":"28","author":"DeVay","year":"2017","journal-title":"Bioconjugate Chem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-23-0609","article-title":"First-in-Human study of the radioligand 68Ga-N188 targeting Nectin-4 for PET\/CT imaging of advanced urothelial carcinoma","volume":"29","author":"Duan","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3253","article-title":"Microtubule-binding agents: a dynamic field of cancer therapeutics","volume":"9","author":"Dumontet","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"B26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1158\/0008-5472.CAN-23-2812","article-title":"Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-Positive breast cancer","volume":"84","author":"Gedik","year":"2024","journal-title":"Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-23-1283","article-title":"Clinical and genomic landscape of FGFR3-Altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience","volume":"29","author":"Guercio","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e2306309","DOI":"10.1002\/advs.202306309","article-title":"Rational identification of novel antibody-drug conjugate with high bystander killing effect against heterogeneous tumors","volume":"11","author":"Guo","year":"2024","journal-title":"Adv. Sci (Weinh)."},{"key":"B30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","article-title":"The biology and rationale of targeting nectin-4 in urothelial carcinoma","volume":"18","author":"Heath","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of Nectin-4 in bladder urothelial carcinoma in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1021\/acs.nanolett.2c00540","article-title":"A lysosome-targeting self-condensation prodrug-nanoplatform system for addressing drug resistance of cancer","volume":"22","author":"Hou","year":"2022","journal-title":"Nano Lett."},{"key":"B33","doi-asserted-by":"publisher","first-page":"04768","DOI":"10.1016\/j.eururo.2025.10.009","article-title":"Efficacy and safety of disitamab vedotin combined with gemcitabine as neoadjuvant therapy in muscle-invasive bladder cancer: an open-label, multicenter, single-arm, phase 2 trial","author":"Huang","year":"2025","journal-title":"Eur. Urol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1537808","DOI":"10.3389\/fimmu.2025.1537808","article-title":"Redefining bladder cancer treatment: innovations in overcoming drug resistance and immune evasion","volume":"16","author":"Huang","year":"2025","journal-title":"Front. Immunol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1200\/JCO.2023.41.16_suppl.4573","article-title":"Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients with advanced urothelial carcinoma (aUC): analysis of the UNITE study","volume":"41","author":"Jindal","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"101086","DOI":"10.1016\/j.drup.2024.101086","article-title":"Spotlight on ideal target antigens and resistance in antibody-drug conjugates: strategies for competitive advancement","volume":"75","author":"Jiang","year":"2024","journal-title":"Drug Resist. Updat. Rev. Comment. Antimicrob. Anticancer Chemother."},{"key":"B36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.biomaterials.2016.10.036","article-title":"Pre-instillation of tumor microparticles enhances intravesical chemotherapy of nonmuscle-invasive bladder cancer through a lysosomal pathway","volume":"113","author":"Jin","year":"2017","journal-title":"Biomaterials"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e2312855121","DOI":"10.1073\/pnas.2312855121","article-title":"Tumor-neutrophil cross talk orchestrates the tumor microenvironment to determine the bladder cancer progression","volume":"121","author":"Jing","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B38","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3322\/caac.21657","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA a Cancer Journal Clinicians"},{"key":"B39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Sci. (New York, N.Y.)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.2147\/DDDT.S135571","article-title":"\u201cIntracellular trafficking of new anticancer therapeutics: antibody\u2013drug conjugates,\u201d","volume":"11","author":"Kalim","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2533488","DOI":"10.1080\/2162402X.2025.2533488","article-title":"Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates","volume":"14","author":"Kepp","year":"2025","journal-title":"Oncoimmunology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1158\/1535-7163.MCT-21-0580","article-title":"Cellular-resolution imaging of bystander payload tissue penetration from antibody-drug conjugates","volume":"21","author":"Khera","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.euf.2024.04.001","article-title":"Biomarkers of response to Anti-NECTIN4 antibody-drug conjugate enfortumab vedotin in urothelial cancer","volume":"10","author":"Kl\u00fcmper","year":"2024","journal-title":"Eur. Urol. Focus"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41585-024-00951-2","article-title":"Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer","volume":"22","author":"Kl\u00fcmper","year":"2025","journal-title":"Nat. Rev. Urol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e2504798","DOI":"10.1002\/adma.202504798","article-title":"mTORC1 selective nano-inhibitor by disrupting the lysosomal Arginine-SLC38A9-mTORC1-CDKs axis for precision bladder cancer therapy","volume":"37","author":"Kong","year":"2025","journal-title":"Adv. Mater."},{"key":"B48","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41585-022-00608-y","article-title":"The dynamic roles of the bladder tumour microenvironment","volume":"19","author":"Lee","year":"2022","journal-title":"Nat. Rev. Urol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jncc.2023.02.003","article-title":"Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer","volume":"3","author":"Lei","year":"2023","journal-title":"J. Natl. Cancer Cent."},{"key":"B50","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody-drug conjugates: a review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"B51","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","article-title":"Epidemiology, screening, and prevention of bladder cancer","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1158\/1078-0432.CCR-23-3924","article-title":"Sacituzumab govitecan demonstrates efficacy across tumor Trop-2 expression levels in patients with advanced urothelial cancer","volume":"30","author":"Loriot","year":"","journal-title":"Clin. Cancer Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","article-title":"TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes","volume":"35","author":"Loriot","year":"","journal-title":"Ann. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1158\/1078-0432.CCR-23-3738","article-title":"FDA approval summary: Enfortumab vedotin plus pembrolizumab for cisplatin-ineligible locally advanced or metastatic urothelial carcinoma","volume":"30","author":"Maguire","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41571-023-00849-9","article-title":"Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives","volume":"21","author":"Marra","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.annonc.2023.09.3114","article-title":"The double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma","volume":"35","author":"McGregor","year":"2024","journal-title":"Ann. Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1158\/1078-0432.CCR-25-3103","article-title":"Predictive biomarkers of antibody-drug conjugate efficacy for solid tumors: current challenges and the potential role of quantitative proteomics","volume":"32","author":"McNamee","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1124\/dmd.121.000503","article-title":"Simulating the selection of resistant cells with bystander killing and antibody coadministration in heterogeneous human epidermal growth factor receptor 2-Positive tumors","volume":"50","author":"Menezes","year":"2022","journal-title":"Drug Metabolism Dispos. Biol. Fate Chem."},{"key":"B61","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev-physiol-012110-142317","article-title":"Lysosomal acidification mechanisms","volume":"74","author":"Mindell","year":"2012","journal-title":"Annu. Rev. Physiology"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.3390\/cancers15092565","article-title":"Diagnostic and prognostic roles of urine Nectin-2 and Nectin-4 in human bladder cancer","volume":"15","author":"Miyake","year":"2023","journal-title":"Cancers"},{"key":"B63","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","article-title":"Progress in systemic therapy for advanced-stage urothelial carcinoma","volume":"21","author":"Nadal","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S1470-2045(26)00050-1","article-title":"Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study","volume":"27","author":"Necchi","year":"2026","journal-title":"Lancet. Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"102395","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives","volume":"106","author":"Nicol\u00f2","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"B130","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O\u2019Donnell","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1200\/JCO.23.00013","article-title":"Antibody-drug conjugates in lung cancer: recent advances and implementing strategies","volume":"41","author":"Passaro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41573-019-0032-5","article-title":"Targeting metabolism to regulate immune responses in autoimmunity and cancer","volume":"18","author":"Patel","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B68","doi-asserted-by":"publisher","first-page":"102351","DOI":"10.1016\/j.ctrv.2022.102351","article-title":"The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: a systematic review and future perspectives","volume":"104","author":"Patelli","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e455","DOI":"10.1002\/mco2.455","article-title":"Targeted therapies in bladder cancer: signaling pathways, applications, and challenges","volume":"4","author":"Peng","year":"2023","journal-title":"MedComm"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-Year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"","journal-title":"Ann. Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"","journal-title":"Ann. Oncol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"188902","DOI":"10.1016\/j.bbcan.2023.188902","article-title":"Targeting Trop-2 in cancer: recent research progress and clinical application","volume":"1878","author":"Qiu","year":"2023","journal-title":"Biochimica Biophysica Acta. Rev. Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41585-025-01075-x","article-title":"HER2 and urothelial carcinoma: current understanding and future directions","volume":"23","author":"Raggi","year":"2026","journal-title":"Nat. Rev. Urol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"123756","DOI":"10.1016\/j.ijpharm.2023.123756","article-title":"An iodine-labelled antibody-drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma","volume":"651","author":"Ren","year":"2024","journal-title":"Int. J. Pharm."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41467-024-45714-0","article-title":"Gene-expression-based T-Cell-to-Stroma enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer","volume":"15","author":"Rijnders","year":"2024","journal-title":"Nat. Commun."},{"key":"B77","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity","volume":"77","author":"R\u00edos-Luci","year":"2017","journal-title":"Cancer Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrurol.2015.111","article-title":"Targeting glycogen metabolism in bladder cancer","volume":"12","author":"Ritterson Lew","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/Programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2","DOI":"10.20517\/cdr.2025.151","article-title":"Identification of antibody-drug conjugate payloads that are substrates of ATP-Binding cassette drug efflux transporters","volume":"9","author":"Roth","year":"2026","journal-title":"Cancer Drug Resist."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3389\/fimmu.2019.01296","article-title":"Conceptual approaches to modulating antibody effector functions and circulation half-life","volume":"10","author":"Saunders","year":"2019","journal-title":"Front. Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e00617","DOI":"10.1002\/prp2.617","article-title":"Characterization of T-DM1-resistant breast cancer cells","volume":"8","author":"Sauveur","year":"2020","journal-title":"Pharmacol. Res. and Perspect."},{"key":"B83","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3322\/caac.21670","article-title":"Metabolomics in cancer research and emerging applications in clinical oncology","volume":"71","author":"Schmidt","year":"2021","journal-title":"CA a Cancer Journal Clinicians"},{"key":"B84","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41585-019-0226-y","article-title":"The multifaceted immune regulation of bladder cancer","volume":"16","author":"Schneider","year":"2019","journal-title":"Nat. Rev. Urol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrd1957","article-title":"Antibody targeted drugs as cancer therapeutics","volume":"5","author":"Schrama","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"B128","doi-asserted-by":"publisher","first-page":"23523735251317865","DOI":"10.1177\/23523735251317865","article-title":"Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer","volume":"11","author":"Shanmugam","year":"2025","journal-title":"Bladder Cancer"},{"key":"B86","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.drup.2014.11.001","article-title":"Antibody-targeted drugs and drug resistance--challenges and solutions","volume":"18","author":"Shefet-Carasso","year":"2015","journal-title":"Drug Resist. Updat. Rev. Comment. Antimicrob. Anticancer Chemother."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2-Expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1632705","DOI":"10.3389\/fimmu.2025.1632705","article-title":"Another power of antibody-drug conjugates: immunomodulatory effect and clinical applications","volume":"16","author":"Shi","year":"2025","journal-title":"Front. Immunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"e110620","DOI":"10.15252\/embj.2022110620","article-title":"IDH2 stabilizes HIF-1\u03b1-induced metabolic reprogramming and promotes chemoresistance in urothelial cancer","volume":"42","author":"Shigeta","year":"2023","journal-title":"EMBO Journal"},{"key":"B90","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","article-title":"Antibody-drug conjugates in cancer therapy","volume":"64","author":"Sievers","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/ijc.11477","article-title":"HER-2 and TOP2A coamplification in urinary bladder cancer","volume":"107","author":"Simon","year":"2003","journal-title":"Int. J. Cancer"},{"key":"B92","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40259-023-00606-5","article-title":"Antibody-drug conjugates in the treatment of urothelial cancer","volume":"37","author":"Singh","year":"2023","journal-title":"BioDrugs"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1158\/1535-7163.MCT-06-0026","article-title":"Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin\/p97","volume":"5","author":"Smith","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"B94","doi-asserted-by":"publisher","first-page":"8956","DOI":"10.3390\/ijms24108956","article-title":"Hypoxia is associated with increased immune infiltrates and both anti-tumour and immune suppressive signalling in muscle-invasive bladder cancer","volume":"24","author":"Smith","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B95","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1158\/1535-7163.MCT-17-0403","article-title":"Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1)","volume":"17","author":"Sung","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"B96","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jconrel.2025.01.060","article-title":"Receptor-ligand interactions for optimized endocytosis in targeted therapies","volume":"380","author":"Sung","year":"2025","journal-title":"J. Control. Release"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"2220466","DOI":"10.1080\/19420862.2023.2220466","article-title":"A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells","volume":"15","author":"Tan","year":"2023","journal-title":"mAbs"},{"key":"B99","first-page":"878","article-title":"Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy","volume":"8","author":"Tannock","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3322\/caac.21705","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA a Cancer Journal Clinicians"},{"key":"B126","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3892\/ijo.2023.5567","article-title":"Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein (Review)","volume":"63","author":"Tian","year":"2023","journal-title":"Int. J. Oncol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s11912-025-01713-y","article-title":"Chemotherapeutic drug-antibody conjugates (ChemoBodies): recent advances and future directions","volume":"27","author":"Tiwatane","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"B102","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.3390\/curroncol29060312","article-title":"Trop-2 in upper tract urothelial carcinoma","volume":"29","author":"Tomiyama","year":"2022","journal-title":"Curr. Oncol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"e2509001","DOI":"10.71150\/jm.2509001","article-title":"Metabolite-mediated mechanisms linking the urinary microbiome to bladder cancer","volume":"63","author":"Tr\u1ea7n","year":"2025","journal-title":"J. Microbiol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/sj.leu.2403350","article-title":"High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (mylotarg) treatment in acute myeloid leukemia patients","volume":"18","author":"van der Velden","year":"2004","journal-title":"Leukemia"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/cas.13253","article-title":"Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells","volume":"108","author":"Wang","year":"2017","journal-title":"Cancer Sci."},{"key":"B108","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1038\/s41467-018-05992-x","article-title":"EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer","volume":"9","author":"Wang","year":"2018","journal-title":"Nat. Commun."},{"key":"B109","doi-asserted-by":"publisher","first-page":"8363","DOI":"10.3390\/ijms21218363","article-title":"Lactic acid and an acidic tumor microenvironment suppress anticancer immunity","volume":"21","author":"Wang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B110","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41419-024-06665-y","article-title":"A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death and Dis."},{"key":"B111","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. and Oncol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.tips.2025.10.005","article-title":"Artificial intelligence in antibody-drug conjugate development","volume":"46","author":"Wang","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors","volume":"17","author":"Wei","year":"2024","journal-title":"J. Hematol. and Oncol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.20892\/j.issn.2095-3941.2025.0284","article-title":"Advances in antibody-drug conjugates for urothelial carcinoma treatment","volume":"22","author":"Wei","year":"2025","journal-title":"Cancer Biol. and Med."},{"key":"B115","doi-asserted-by":"publisher","first-page":"2498162","DOI":"10.1080\/19420862.2025.2498162","article-title":"Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations","volume":"17","author":"Wen","year":"2025","journal-title":"mAbs"},{"key":"B116","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2020","journal-title":"Eur. Urol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.ccell.2024.11.001","article-title":"Molecular subtyping in urothelial carcinoma treatment","volume":"42","author":"Wu","year":"2024","journal-title":"Cancer Cell"},{"key":"B118","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1158\/0008-5472.CAN-25-0024","article-title":"Targeting sialylation enhances the therapeutic efficacy of the Nectin-4-Targeted antibody-drug conjugate enfortumab vedotin in bladder cancer","volume":"86","author":"Wu","year":"2026","journal-title":"Cancer Res."},{"key":"B119","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1158\/1078-0432.CCR-14-2035","article-title":"A novel Anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin-based ADCs","volume":"21","author":"Yu","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B120","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1186\/s12885-019-5814-y","article-title":"Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms","volume":"19","author":"Zeng","year":"2019","journal-title":"BMC Cancer"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1591191","DOI":"10.3389\/fimmu.2025.1591191","article-title":"Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"22198","DOI":"10.1038\/s41598-024-72918-7","article-title":"Intratumoral microbiota as a novel prognostic indicator in bladder cancer","volume":"14","author":"Zhang","year":"2024","journal-title":"Sci. Rep."},{"key":"B123","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-025-01752-9","article-title":"Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies","volume":"18","author":"Zhou","year":"2025","journal-title":"J. Hematol. and Oncol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"100849","DOI":"10.1016\/j.medj.2025.100849","article-title":"Antibody-drug conjugates: current challenges and innovative solutions for precision cancer therapy","author":"Zhou","year":"2025","journal-title":"Med"},{"key":"B125","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","article-title":"Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment","volume":"25","author":"Zippelius","year":"2025","journal-title":"Nat. Rev. Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1882868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:32:00Z","timestamp":1786941120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1882868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":130,"alternative-id":["10.3389\/fphar.2026.1882868"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1882868","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1882868"}}